We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck.
- Authors
Pivot; Cals; Cupissol; Guardiola; Tchiknavorian; Guerrier; Merad; Wendling; Barnouin; Savary; Thyss; Schneider
- Abstract
Objective: Twenty-seven patients with recurrent squamous cell carcinoma of the head and neck were entered in a multicenter study to determine the efficacy of the paclitaxel-carboplatin association. Methods: Standard eligibility criteria applied, i.e. measurable disease, and chemotherapy given as induction treatment or concomitant chemoradiotherapy was allowed if completed more than 6 months prior to the study. Every 21 days, paclitaxel 175 mg/m[sup 2] and carboplatin AUC 6 were administered. The patient group included 3 females and 24 males with a median age of 61 years (range 39–75 years). Results: All patients were assessable for toxicity and 24 for responses. Main grade 3–4 toxicities were: neutropenia (62.9%), febrile neutropenia (18.5%), anemia (11.1%), thrombocytopenia (14.8%), mucositis (7.4%) and vomiting (7.4%). Among the intent-to-treat population, 29.6% of patients had an objective response, with a median response duration of 4.2 months (range 1–5.7 months). Stable and progressive disease were observed in 11.1 and 48.1% of patients, respectively. The median overall survival was 7.2 months (range 0.5–10.9 months). Conclusion: From these data, paclitaxel-carboplatin seems to have an activity in recurrent squamous cell carcinoma of the head and neck, but the high level of toxicity highlights the need to search for a safer chemotherapy combination.Copyright © 2001 S. Karger AG, Basel
- Subjects
PACLITAXEL; ANTINEOPLASTIC agents; SQUAMOUS cell carcinoma; CANCER; HEAD &; neck cancer
- Publication
Oncology, 2001, Vol 60, Issue 1, p66
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000055299